JP2011502521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502521A5 JP2011502521A5 JP2010533337A JP2010533337A JP2011502521A5 JP 2011502521 A5 JP2011502521 A5 JP 2011502521A5 JP 2010533337 A JP2010533337 A JP 2010533337A JP 2010533337 A JP2010533337 A JP 2010533337A JP 2011502521 A5 JP2011502521 A5 JP 2011502521A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion polypeptide
- fusion
- oligomeric
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 230000004927 fusion Effects 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000013638 trimer Substances 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98728707P | 2007-11-12 | 2007-11-12 | |
| PCT/US2008/083190 WO2009102357A2 (en) | 2007-11-12 | 2008-11-12 | Hiv-1 envelope glycoprotein oligomer and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502521A JP2011502521A (ja) | 2011-01-27 |
| JP2011502521A5 true JP2011502521A5 (enExample) | 2011-11-17 |
Family
ID=40957413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533337A Pending JP2011502521A (ja) | 2007-11-12 | 2008-11-12 | Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8597658B2 (enExample) |
| EP (1) | EP2235065A4 (enExample) |
| JP (1) | JP2011502521A (enExample) |
| AU (1) | AU2008350273B2 (enExample) |
| CA (1) | CA2705373A1 (enExample) |
| WO (1) | WO2009102357A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013295647B2 (en) * | 2012-07-26 | 2018-02-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| WO2017192434A1 (en) * | 2016-05-02 | 2017-11-09 | The Scripps Research Institute | Compositions and methods related to hiv-1 immunogens |
| CA3077340A1 (en) * | 2017-11-17 | 2019-05-23 | Grifols Diagnostic Solutions Inc. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292646A (en) * | 1991-02-06 | 1994-03-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| US6039957A (en) * | 1993-12-10 | 2000-03-21 | United States Of America, As Represented By The Department Of Health And Human Services | Oligomeric HIV-1 envelope glycoproteins |
| EP1104310B1 (en) * | 1998-08-04 | 2009-07-01 | The Henry M. Jackson Foundation for the advancement of Military Medicine, Inc. | Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response |
| CA2384271A1 (en) * | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
| WO2003077838A2 (en) * | 2002-03-05 | 2003-09-25 | National Institutes Of Health Office Of Technology Transfer | Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens |
| JP5290576B2 (ja) * | 2004-08-27 | 2013-09-18 | ザ ヘンリー エム． ジャクソン ファンデーション フォー ジ アドバンスメント オブ ミリタリー メディシン インコーポレイテッド | 修飾されたｈｉｖ−１エンベロープタンパク質 |
-
2008
- 2008-11-12 JP JP2010533337A patent/JP2011502521A/ja active Pending
- 2008-11-12 AU AU2008350273A patent/AU2008350273B2/en not_active Ceased
- 2008-11-12 CA CA2705373A patent/CA2705373A1/en not_active Abandoned
- 2008-11-12 WO PCT/US2008/083190 patent/WO2009102357A2/en not_active Ceased
- 2008-11-12 US US12/742,272 patent/US8597658B2/en not_active Expired - Fee Related
- 2008-11-12 EP EP08872458A patent/EP2235065A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| AU2020219803B2 (en) | Nanoparticle-based influenza virus vaccines and uses thereof | |
| RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
| JP2010166916A5 (enExample) | ||
| JP2011528901A5 (enExample) | ||
| MX348360B (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
| JP2010502207A5 (enExample) | ||
| Robinson | Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2012501959A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2012095652A5 (enExample) | ||
| PH12012500849A1 (en) | Mycobacterial vaccines | |
| NZ600348A (en) | Anti-c5a binding moieties with high blocking activity | |
| JP2015212284A5 (enExample) | ||
| UA110473C2 (uk) | Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1 | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| JP2015529678A5 (enExample) | ||
| JP2014521313A5 (enExample) | ||
| JP2013520487A5 (enExample) | ||
| JP2015505309A5 (enExample) | ||
| SI2731973T1 (en) | A bacterial host strain expressing a recombinant DSBC | |
| EP2292645A3 (en) | Small Streptococcus pyogenes antigens and their use |